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Thousands of women diagnosed with breast cancer each year receive breast-conserving
surgery followed by adjuvant radiation therapy. For women with left-sided breast cancer,
there is risk of potential cardiotoxicity from the radiation therapy. As data have become avail-
able to quantify the risk of cardiotoxicity from radiation, strategies have also developed to
reduce the dose of radiation to the heart without compromising radiation dose to the breast.
Several broad categories of techniques to reduce cardiac radiation doses include breath
hold techniques, prone positioning, intensity-modulated radiation therapy, and accelerated
partial breast irradiation, as well as many small techniques to improve traditional three-
dimensional conformal radiation therapy. This review summarizes the published scientific
literature on the various techniques to decrease cardiac irradiation in women treated to the
left breast for breast cancer after breast-conserving surgery.
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INTRODUCTION
The American Cancer Society estimates that in 2014 about 232,000
new cases of invasive breast cancer will be diagnosed, as well as
62,500 cases of breast carcinoma in situ (1). The majority of these
women will receive breast-conserving surgery followed by radi-
ation. Breast irradiation has been shown to decrease the risk of
local recurrence after breast-conserving surgery with few adverse
effects (2). One of the most concerning complications of breast
radiotherapy is cardiotoxicity from radiation to the heart.
Early studies showed decreased left ventricular function in
breast cancer patients treated with radiation (3). Excess risk of
cardiac mortality due to radiation, from two European random-
ized trials involving five different techniques, has been estimated
to be 1.8% (4), though this data also suggested that only heart
doses greater than 30 Gray (Gy) were important to calculate risk
of cardiac toxicity. Cardiotoxicity is most frequently reported as
decreased myocardial function or coronary artery disease (also
reported as ischemic heart disease or decreased cardiac perfusion).
However, less common toxicities can include myocardial infarc-
tion, congestive heart failure, pericarditis, arrhythmias, angina,
or valve dysfunction (5, 6). While generalized decreased cardiac
function has been generally reported, some studies in this review
have specifically shown decreased left ventricular or left anterior
descending coronary artery (LAD) function or perfusion after
radiation.
A review of over 1600 patients with 16 years of follow-up found
that left-sided breast cancer patients treated with radiation had a
38% increase in cardiovascular disease compared to right-sided
cancer patients, though the rates of cardiovascular disease did not
correlate with volume of heart irradiated (7). Recently, another
review of 2168 women who underwent radiotherapy for breast
cancer in Sweden and Denmark found that the average mean heart
dose was 4.9 Gy and that there was a significant linear correlation
between mean heart dose and rate of major coronary events, with
an increase of 7.4% per Gy (8). Another study estimated the risk
of cardiotoxicity to increase 4% per Gy mean heart dose (9).
It should be remembered that for patients with long follow-up,
the treatment techniques used may be relatively outdated com-
pared to those used today, and therefore, their reported cardiac
doses may not represent typical doses today. In addition, for such
patients, 3D dose and image data, which are routinely available
today, were generally not available in many older studies, requiring
more uncertain methods of estimating cardiac dose. While rates of
cardiotoxicity are improving, and methods of delivering and quan-
tifying dose of radiation to the heart have become more sophis-
ticated, reducing potential for any cardiotoxicity remains one of
the primary aims of improving adjuvant radiation techniques for
patients with left-sided cancers.
This paper will focus on treatment of patients treated with
radiation after breast-conserving surgery. Treatment fields, angles,
and other radiotherapy techniques may be different for post-
mastectomy patients compared to patients with intact breasts. It
is beyond the scope of this paper to attempt to discuss all aspects
of plan evaluation for the studies discussed, such as planning tar-
get volume coverage, dose homogeneity, and dose to other organs.
This review will focus solely on techniques to decrease radiation
to the heart for women receiving radiation to the left breast.
MATERIALS AND METHODS
A Pubmed literature search was performed on March 5, 2014
to review any papers discussing breast cancer heart dosimetry.
Articles were excluded if they reviewed non-breast cancer data,
post-mastectomy radiation, exclusively evaluated patients with
pectus excavatum, bilateral breast irradiation, or did not have heart
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dosimetric data. Articles were reviewed specifically for data from
patients treated to the left breast. For this review, all studies are
assumed to deliver whole breast irradiation unless partial breast
treatment is stated.
RESULTS
SUPINE 3D
Traditionally, breast cancer has been treated in the supine posi-
tion with arms above the head with two opposed tangent photon
fields. The earliest data on cardiac toxicity originated from the
Stockholm Breast Cancer trial, which treated patients to 45 Gy at
1.8 Gy per fraction, and found a 15-year excess cardiac mortality of
6.8% attributed to the radiation (10). A review of patients treated
in that trial estimated the mean volume of heart treated to the 50%
isodose (22.5 Gy) to be 25% (11). One of the first trials to show
an alternative approach to reduce heart dose was a review of the
plans of 100 women with left-sided T1N0MO breast cancer sta-
tus post-lumpectomy treated with three-dimensional conformal
radiation therapy (3DCRT) planning to 50 Gy at 2 Gy per frac-
tion, which reviewed the dose to the heart for these patients and
found the volume treated to 50% isodose to be 5.7% (approx-
imately 33 cc) (12). This significant reduction of heart dose led
to the widespread adoption of 3D conformal planning for breast
cancer. Some have shown that simply using 3DCRT to account for
individual organ location, by putting a limit of 1 cm of heart in the
tangent field, would cause at most a 1 per thousand patient risk
of cardiac mortality (13). Several other studies have also shown
reductions in planned heart dose with 3D conformal compared to
two-dimensional planning (14, 15). However, one study showed
no difference in mean heart dose,V20, or V5 heart dose comparing
2D, standard 3DCRT, and field-in-field (FiF) techniques (16).
Since the adoption of 3DCRT, many techniques have been
attempted to further reduce cardiac radiation dose. A large study
involving 217 left-sided breast cancer patients evaluated 3DCRT vs
multi-segmented conformal radiation therapy and found no dif-
ference in mean heart dose (17). Another study confirmed this
finding (18). A study evaluating tangential single wedge, dou-
ble wedge, and FiF techniques found no significant differences
in cardiac dose (19). A single study evaluating treating women
with large breasts in the left lateral decubitus position was able to
achieve a mean heart dose of 1.35 Gy for left-sided cancers (20).
Using FiF planning can produce lower heart mean dose, V10, and
V20 compared to standard 3DCRT plans (21). One study found
that treating patients with their bra on decreased V5 to the heart
from 9.8 to 2.7% (22). Hypofractionated whole breast regimens
are becoming more common and have been shown to have equal
slightly improved 2 Gy dose equivalent doses to the heart (23, 24).
PRONE
The largest and most current experience with prone breast treat-
ment includes 200 women with left-sided breast cancer and has
shown a significant decrease in in-field heart volumes compared
to supine tangent plans with a mean reduction of 7.5 cm3, which
corresponded to a 85.7% reduction in in-field heart volume (25).
However, there was no benefit for women with smaller breasts (less
than 750 cm3), and 15% of women overall had decrease in in-field
heart volume when planned in the supine position. The second
largest study comparing supine and prone planning, comparing
whole breast and partial breast plans, found that prone position-
ing decreased cardiac doses for large breasted women but increased
cardiac doses for women with smaller breast volume (26), a finding
that has also been concluded in other studies (27, 28). One study
found improvement in heart doses with prone positioning, but at
the cost of a 50% reduction in coverage of the axillary nodes (29).
Some smaller series have found no difference between supine and
prone heart doses (29–31). Figure 2 provides examples of prone
breast and an external beam accelerated partial breast irradiation
(APBI) plans with corresponding isodose lines.
INTENSITY-MODULATED RADIATION THERAPY
As has been shown in many sites treated with intensity-modulated
radiation therapy (IMRT), left-sided breast cancer patients treated
with IMRT limits high dose to the heart without limiting low
doses (32–35). Different techniques, including forward-planned
IMRT, inverse-planned IMRT, and modulated arc therapies have
been studied. A study of multiple partial arc volume-modulated
arc therapy had a mean V25 to the heart of 2.52% of the heart
volume, while having a mean total dose of 7.61 Gy (36). IMRT
incorporating a simultaneous boost, even with respiratory gat-
ing, showed a mean heart dose of 22.98 Gy but reduced treatment
duration by 6 fractions (37). Whether standard sequential boost
or IMRT concomitant boost was used did not significantly affect
heart dose (38). Forward-planned IMRT has been shown in one
study to significantly reduce mean heart dose compared to inverse
IMRT and arc radiotherapy (5.46 vs 15.48 vs 12.73 Gy) (39).
Many studies comparing IMRT to 3DCRT have shown
decreased heart mean,V25, and V30 with IMRT compared to stan-
dard tangent fields (40–47), however, with no improvement over
tangents with FiF (48). Other studies have failed to show a signif-
icant difference in most heart constraints for IMRT over 3DCRT
(49). The largest study comparing 3DCRT vs IMRT, comparing
201 forward-planned IMRT cases to 131 3DCRT plans, strati-
fied by breast size and use of supraclavicular nodal irradiation,
found a non-significant trend toward reduced heart constraints
with IMRT (50).
TECHNOLOGICAL SOLUTIONS
Breath hold, accomplished by having the patient take and hold
a deep inspiration during CT simulation and during treatment
each day, has been shown to significantly reduce heart dose. Sev-
eral studies have shown that deep inspiration breath hold (DIBH)
compared to free breathing (FB) reduced mean heart dose and sev-
eral other dose constraints to the heart by 50%, with mean heart
doses around 2–3 Gy (51–55). A comparison of thoracic anatomy
and radiation isodose lines with FB and DIBH can be seen in
Figure 1, which demonstrates how the breath hold can change
thoracic anatomy to potentially reduce cardiac dose received of
radiation. A selective approach to using DIBH was used in one
study, which evaluated 53 left breast patients and evaluated all
patients with standard tangent field plans. Any patients with
greater than 10 cm3 of heart receiving 50% of the prescription
dose were selected for DIBH IMRT, and these DIBH IMRT cases
had significantly reduced whole heart and LAD doses (56). One
study combined DIBH with IMRT and significantly reduced heart
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FIGURE 1 | Example of (A) free breathing and (B) deep inspiration breath hold plans for a single patient.
FIGURE 2 | Examples of (A) prone breast and (B) external beamAPBI plans.
V30 in two-thirds of the patients and was able to avoid any heart
irradiation in 22% of cases (57). Another study, using cardiac MRI,
similarly found that breath hold could displace the heart entirely
out of the radiation field in 21% of patients (58).
One consideration of breath hold techniques is inter-fraction
reproducibility of patient geometry and anatomy. When the breath
hold is voluntary, respiratory coaching is required to ensure consis-
tency. Two studies have shown good inter-fraction reproducibility
with DIBH (53, 59). Monitoring technology such as magnetic sen-
sors or real-time surface imaging can be used to verify and improve
voluntary breath hold reproducibility (59, 60). Several studies rely
on technology sometimes referred to as active breathing control, in
which a patient breathes through a device that monitors breathing
air volumes and automatically holds the patient’s breath at pre-
specified volumes for a defined period of time (55, 57, 61–64).
Some studies have explored the use of gating rather than breath
hold to address intra-fraction respiratory motion (60, 65). Even
with respiratory motion management such as breath hold, cardiac
motion may still be an issue. Under breath hold conditions, one
study showed that the LAD can show substantial displacement
due to cardiac contraction (66). Another study used fluoroscopy
to show potentially significant cardiac motion that was not evident
using 4DCT techniques (67).
Changing the radiation particle from photons to protons and
using MRI-linacs for photon treatment delivery are two newer
approaches to improving treatment delivery. Proton radiotherapy
is not commonly used for the breast; however, one study projected
that a reduced risk of cardiac mortality might be achieved, based
on planned cardiac doses, for proton and IMRT plans compared
to 3DCRT (68). A study of breast radiotherapy using integrated
MRI-linacs found no difference in heart D2cc or V25 for whole
breast tangential and 7-field IMRT APBI plans (69). One potential
application for future MRI-linacs is the appropriate application of
a reversible transverse magnetic field, which in simulation resulted
in a 26.0% mean heart dose reduction (70).
APBI
Accelerated partial breast irradiation is a newer technique in
women with low risk of recurrence for breast cancer to treat only
the lumpectomy cavity with a small margin, rather than the whole
breast and regional lymph nodes. Only women at least 60 years
old with T1, node negative, estrogen receptor positive, unifocal
or unicentric breast cancers with no lymphovascular invasion and
negative margins are fully “suitable” for APBI, with a select group
also considered “cautionary,” per the American Society for Radi-
ation Oncology (71). More recently, APBI guidelines were also
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created by the American Brachytherapy Society with slightly differ-
ent criteria for “suitable” patients, such as slightly older age and no
DCIS allowed (72). However, these guidelines are created by con-
sensus panels for patients off protocol, rather than by randomized
trials with set selection criteria. While APBI is only available for a
select group of breast cancer patients, it is often able to significantly
reduce dose to nearby structures including the heart.
A few studies have compared whole breast irradiation to ABPI.
A study evaluating APBI using IMRT compared to whole breast
using FiF planning (using radiobiologically adjusted results to
account for the different fractionations) found that the APBI
plan reduced the heart mean from 3.17 to 0.80 Gy (p= 0.002)
using APBI and reduced V5 from 8.75 to 4.94% (p= 0.041) (73).
Another review of patients being treated on NSABP-B39 for exter-
nal beam APBI compared to plans for whole breast irradiation has
significantly improved V2.5, V5, and V10 for lateral lumpectomy
cavities but not for medial cavities, though V20 was improved
with APBI regardless of lumpectomy location (74). Mammosite
brachytherapy APBI compared to whole breast irradiation has
been shown to significantly reduce maximum heart dose and V5,
but not mean heart dose orV10 in one study (75),but single-source
APBI brachytherapy did show an improvement in mean heart dose
over whole breast from 2.52 to 1.65 Gy in another study (76).
Accelerated partial breast irradiation can be delivered via exter-
nal beam radiation or via brachytherapy catheter(s) placed in the
lumpectomy cavity. Studies of brachytherapy APBI have shown
mean heart dose between 1.65 and 2.45 Gy and mean V5 between
1 and 59.2% (77–80). One study achieved a mean maximum
heart doses around 2.2 Gy in both Mammosite and Clearpath
brachytherapy catheters, though patients in this study have lesions
closer to skin than chest wall (81). External beam studies have
shown mean heart doses of 1.2 Gy and V5 of 1% (82, 83). RTOG
0413 showed external partial breast irradiation with a mean V5
value at 1.1% for left-sided patients (84).
Accelerated partial breast irradiation with protons has been
shown to be very effective at limiting heart dose with one study
showing no dose greater than 3 Gy to the heart (85). One study
evaluating volumetric-modulated arc radiotherapy (VMAT) was
able to achieve an APBI plan with a mean heart dose of 0.72 Gy,
which was further reduced to 0.34 Gy (a 53% reduction) when
VMAT was combined with dynamic couch rotation to account for
respiratory motion (86). When evaluating IMRT, VMAT, and con-
tinuous arc rotation of the couch APBI plans separately, compared
to a 3DCRT APBI plan, the IMRT and continuous arc plans were
able to significantly reduce the mean heart V5 from 3 to 1.1% and
1.7%, respectively (87). Another study found that for pendulous
breasts treated prone with IMRT APBI combined with dynamic
couch motion could produce a plan that would deliver less than
0.1% of the prescribed dose to the heart (88).
INTERNAL MAMMARY NODE AND BOOST CARDIAC CONTRIBUTION
Slight variations in dose exist though most studies are close to a
biologic equivalent dose (at 2 Gy per fraction) of 50 Gy, though a
significant variation in the implementation and dose of a boost
to the surgical bed exist between studies. Another difficulty in
evaluating cardiac dose is variability in treatment volume. Vari-
ability in coverage of internal mammary nodes (IMN), axillary,
or supraclavicular nodes exists between studies. Adding axillary
nodal or IMN coverage to tangent fields has been shown to increase
the Dmax of the heart by 7–10% (89). Adding IMN coverage to
whole breast irradiation increases the volume of heart irradiated
by 13.8% for left breast cancers (90). When comparing plans with
IMN in the treatment field, one study found no difference between
wide-field, oblique photon-electron, and perpendicular photon-
electron techniques (91), while another found decreased mean
heart dose, V10, and V20 with wide tangents compared to plans
using a separate IMN field (92).
The use and dose of a boost to the lumpectomy cavity is not
standardized between studies, nor among practitioners, which
contributes to the difficulty in comparing studies. The added mean
heart dose of a 10 Gy boost in four fractions is 0.33 Gy for electron
boost and 0.73 Gy for a photon boost viaVMAT (93). Other studies
have found decreased cardiac doses for proton and photon com-
pared to electron boosts (94), and comparable V20 for Mammosite
brachytherapy boost compared to electron boost (95).
DISCUSSION
One of the difficulties in comparing studies in radiation cardiac
toxicity is the variable reported parameters to evaluate potential
toxicity. For example, as mentioned previously, early studies eval-
uated the volume receiving 50% of the prescription dose (10–12).
Another study reviewed SPECT perfusion scans in 20 women
6 months after breast radiation and found minimal decrease in
perfusion if RT dose was kept less than 10 Gy and a 20% per-
fusion reduction if greater than 40 Gy (96), suggesting V10 and
V40 as potential targets for plan evaluation. Strain rate imaging
has also been used to evaluate cardiac damage from radiation and
has shown that radiation of left breast patients led to a significant
2% reduction in left ventricle strain after radiation, particularly
observed in regions of the heart exposed to 3 Gy or more (97),
which was observed immediately after radiation and persistent
when evaluated 14 months after radiation (98). Cardiac biomark-
ers have also been evaluated following breast irradiation, and while
there was a significant increase in mean values of troponin I and
Brain Natriuretic Peptide (from 0.007 to 0.014 ng/mL and 123 to
159 pg/mL, respectively), the increase was not above normal ref-
erence values (99). A study of 681 breast cancer patients treated
in Denmark who did not develop ischemic heart disease found
that left-sided breast cancer patients had a mean heart dose of
6 Gy, despite receiving coverage of IMN and supraclavicular fields
(100). Mean heart dose is also used as a common reference dose
constraint given reports of clinical outcomes in studies using this
parameter (8). Table 1 provides a comparison of many studies
that included mean heart dose data; however, caution should be
used in comparing studies, as many studies included low numbers
of patients, and extent of breast and nodal tissue covered differs
from one study to another. Studies have failed to consistently show
that LAD dose is independently predictive of cardiotoxicity more
than whole heart measures and more reproducible from one physi-
cian to another. Therefore, whole heart dose remains a standard
measure at present. However, further data are needed to more
rigorously establish standards for dosimetric cardiac constraints.
Another challenge is defining the volume used to calculate these
dose constraints. Slight variations in heart contours can exist from
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Table 1 | Summary of studies evaluating mean heart dose.
Reference n Treatment technique Mean heart dose (Gy)
(19) 15 3DCRT (with 16 Gy boost). Tangential single wedge vs double wedge vs FiF 3.31 vs 3.31 vs 3.07
(16) 15 2D vs 3D vs FiF 4.42 vs 5.33 vs 5.17
(101, 102) 358 3DCRT 5.1 if treated in 1950s and 3.0 Gy if
treated in 1990s
(17) 217 3DCRT vs multi-segmented conformal radiation therapy 4.8 vs 4.8
(103) 50 3DCRT 2.3
(92) 32 3DCRT including IMNs: 2 plans with separate IMN fields vs wide tangents 6.4 vs 8.1 vs 3.8
(21) 10 Bilateral wedge tangents vs FiF 2.2 vs 1.89
(20) 26 3DCRT in left lateral decubitus position 1.35
(55) 87 3DCRT vs moderate DIBH using active breathing control 4.23 vs. 2.54
(56, 66) 53 3DCRT, if V50>10 cm3, then DIBH IMRT 3.17 vs 1.32
(51) 30 IMRT with simultaneous integrated boost in free breathing and DIBH 6.9 vs 3.9
(52) 12 FB vs DIBH 6.2 vs 3.1
(28) 12 Prone vs supine: wedged tangents, FiF, and multibeam IMRT Wedged tangents: 1.9 vs 3.9. FiF:
1.6 vs 3.3. IMRT: 1.6 vs 2.5
(104) 5 Prone tomotherapy IMRT 8.7
(36) 10 Multiple partial volumetric-modulated arc therapy technique 7.61
(37) 24 Respiratory gated simultaneous integrated boost IMRT 22.98
(39) 10 Forward-IMRT vs inverse-IMRT vs intensity-modulated arc radiotherapy 5.46 vs 15.48 vs 12.73
(33) 20 Small breasted women treated with wedged tangents vs FIF vs T-IMRT vs M-IMRT vs
VMAT
3.7 vs 3.2 vs 2.2 vs 4.4 vs 4.6
(48) 10 3DCRT vs tomotherapy IMRT vs FiF 4.0 vs 3.0 vs 3.0
(38) 11 Hypofractionated concomitant boost radiotherapy using IMRT vs standard sequential
boost technique
2.2 vs 3.2
(42) 13 Tomotherapy vs 3DCRT 1.35 vs 2.22
(44) 14 3D vs IMRT for unfavorable thoracic geometry patients 6.85 vs 8.52
(73) 12 APBI IMRT vs 3DCRT with FiF 0.80 vs 3.17
(75) 6 Mammosite HDR brachytherapy APBI vs 3DCRT 3.5 vs 3.8
(76) 26 Single-source HDR brachytherapy APBI vs 3DCRT 2.52 vs 1.65
(80) 60 Brachytherapy ABPI 2.45
(82) 25 External beam APBI (2 minitangent beams and en face electron beam) 1.2
(93) 14 Dose contribution from 10 Gy/4 fraction boost using few leaf electron collimator-based
modulated electron radiotherapy vs conventional direct electron vs VMAT
0.34 vs 0.33 vs 0.73
n: number of left-breast women in study (total number if left breast not specified); 3DCRT: three-dimensional conformal radiation therapy; FiF: field-in-field; IMN: inter-
nal mammary nodes; DIBH: deep inspiration breath hold; IMRT: intensity-modulated radiation therapy; FB: free breathing; APBI: accelerated partial breast irradiation;
FB: free breathing; HDR: high dose rate; VMAT: volumetric-modulated arc therapy.
one radiation oncologist to another. Also, some have questioned
whether it may be valuable to contour the LAD or other coro-
nary vessels individually and whether to include the pericardium.
For this reason, a heart atlas for CT contouring, developed jointly
by cardiology, cardiac radiology, and radiation oncology, to delin-
eate whole heart and separate coronary vessels, has been shown to
improve accuracy of cardiac contours, and more consistent mean
heart dose reporting, in a tested group of radiation oncologists
(105). While this atlas was verified in a group, it is not used by
all radiation oncologists and has not been used for contouring in
other studies evaluating heart data, because such atlases are still
relatively new. User contour variations, therefore, exist between
studies. Some studies have suggested that the maximum heart
distance in a treatment field, measured anterior to posterior, is
relatively simple and correlates well with mean heart dose and
other cardiac dose measurements (101, 106). However, another
study showed that maximum heart distance only correlated with
dose to the LAD when accounting for respiratory motion (107).
A study of left-sided breast cancer patients where all plans had
LAD, right, and circumflex coronary arteries contoured separately
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found that the mean whole heart dose was 2.3 Gy, and 7.6 Gy to
the LAD, and 2 Gy to the right and circumflex arteries (103). A
recent study of supine standard tangential field plans found that
for every 100 cGy increase in mean heart dose the mean LAD dose
increased by 4.82 Gy, with direct correlations also seen with sev-
eral other constraints, suggesting that LAD dose correlates very
closely with whole heart parameters and LAD does not need to
be contoured separately (108). However, another study using 3
field mono-isocentric partial wide tangents found that 11 of 24
patients had significant variability between mean heart dose and
LAD dose (109). A study of 32 women on a randomized trial,
treated with breast radiotherapy, evaluated the cardiac perfusion
before and 1 year after radiation, and found no significant change
in cardiac perfusion after radiation, even when assessing various
cardiac subvolumes (110).
Variability in dose planned to dose received can exist. It can be
difficult to determine the actual dose received. However, some
studies provide insight into means of limiting the variability
between these doses. It has been shown that patient setup errors
of greater than 3 mm in the posterior direction result in sig-
nificant increased dose to the heart (111, 112). The maximum
anterior/posterior distance of heart in the treatment field has
shown a strong linear correlation with mean heart dose (100).
Even with image guidance, planning margins may be advisable
as variability can exist between bone and/or surface anatomy and
cardiac (25, 60, 111).
The implementation of improving techniques for breast cancer
radiotherapy can significantly reduce the heart radiation dose that
breast cancer patients receive. A review of 358 women treated over
several decades in Sweden found that even though a number of dif-
ferent treatment techniques were used, the overall mean heart dose
to left-sided breast cancer patients was 5.1 Gy in the 1950s com-
pared to 3.0 Gy for women treated in the 1990s (102). However,
it should be remembered that even clear dosimetric advantages in
the treatment planning stage may not translate to improvements
in clinical outcomes (63).
Radiation is not the only factor contributing to cardiac toxi-
city in breast cancer patients, as other aspects of their treatment
can influence cardiac toxicity. For example, a large study involving
doxorubicin and cyclophosphamide chemotherapy with radiation
to either the right or left breast (with or without IMN coverage)
found that the number of cycles of doxorubicin was a more sig-
nificant factor in cardiac toxicity than the amount of heart in the
radiation field (113). Therefore, all aspects of patient care must be
accounted for to reduce cardiac toxicity.
The decision of which treatment planning technique for deliv-
ery of radiotherapy following breast-conserving surgery includes
consideration of many factors about the patient. One important
factor in that decision is radiation doses received to the heart,
as decreasing radiation doses to the heart can potentially prevent
unnecessary cardiotoxicity. Many different techniques are avail-
able, as discussed in this review, to significantly reduce radiation
doses to the heart, thereby providing means to decrease cardiac
toxicity risk for women undergoing such treatment.
Several techniques have been shown to improve cardiac doses
over standard supine 3DCRT tangents. Prone positioning has been
shown to improve cardiac doses for patients with large pendulous
breaths, though not for smaller breasted patients. Breath hold can
also significantly reduce heart dose by displacing the heart away
from the chest wall. APBI can be effective in reducing cardiac
radiation doses though this is dependent on the location of the
tumor/lumpectomy cavity and is only suitable for a select portion
of breast cancer patients. Use of seroma boost and IMN irradia-
tion has been shown to increase cardiac dose, though the cardiac
risk needs to be weighed against the risk of recurrence.
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